Keros Therapeutics (NASDAQ:KROS) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Friday morning,Benzinga reports.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Guggenheim initiated coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 price objective on the stock. Bank of America dropped their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Scotiabank began coverage on Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $55.92 on Friday. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The company has a 50-day moving average price of $59.30 and a 200 day moving average price of $52.26.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same period in the prior year, the company earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. On average, research analysts forecast that Keros Therapeutics will post -5.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds have recently bought and sold shares of the stock. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the second quarter worth about $128,000. Finally, Ameritas Investment Partners Inc. raised its position in shares of Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after buying an additional 324 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.